BACKGROUND: Like stable iodine, radioiodines concentrate in the thyroid gland, increasing thyroid cancer risk in exposed children. Data on exposure to the embryonic/fetal thyroid are rare, raising questions about use of iodine 131 (I-131) in pregnant women. We present here estimated risks of thyroid disease from exposure in utero to I-131 fallout from the Chernobyl nuclear accident. METHODS: We conducted a cross-sectional thyroid screening study (palpation, ultrasound, thyroid hormones, and, if indicated, fine needle aspiration) from 2003 to 2006. Participants were 2582 mother-child pairs from Ukraine in which the mother had been pregnant at the time of the accident on April 26, 1986, or 2 months after the time during which I-131 fallout was still present (1494 from contaminated areas, 1088 in the comparison group). Individual cumulative in utero thyroid dose estimates were derived from estimated I-131 activity in the mother's thyroid (mean 72 mGy; range 0-3230 mGy). RESULTS: There were seven cases of thyroid carcinoma and one case of Hurthle cell neoplasm identified as a result of the screening. Whereas the estimated excess odds ratio per gray for thyroid carcinoma was elevated (excess odds ratio per gray 11.66), it was not statistically significant (P = 0.12). No radiation risks were identified for other thyroid diseases. CONCLUSION: Our results suggest that in utero exposure to radioiodines may have increased the risk of thyroid carcinoma approximately 20 yr after the Chernobyl accident, supporting a conservative approach to medical uses of I-131 during pregnancy.
BACKGROUND: Like stable iodine, radioiodines concentrate in the thyroid gland, increasing thyroid cancer risk in exposed children. Data on exposure to the embryonic/fetal thyroid are rare, raising questions about use of iodine 131 (I-131) in pregnant women. We present here estimated risks of thyroid disease from exposure in utero to I-131 fallout from the Chernobyl nuclear accident. METHODS: We conducted a cross-sectional thyroid screening study (palpation, ultrasound, thyroid hormones, and, if indicated, fine needle aspiration) from 2003 to 2006. Participants were 2582 mother-child pairs from Ukraine in which the mother had been pregnant at the time of the accident on April 26, 1986, or 2 months after the time during which I-131 fallout was still present (1494 from contaminated areas, 1088 in the comparison group). Individual cumulative in utero thyroid dose estimates were derived from estimated I-131 activity in the mother's thyroid (mean 72 mGy; range 0-3230 mGy). RESULTS: There were seven cases of thyroid carcinoma and one case of Hurthle cell neoplasm identified as a result of the screening. Whereas the estimated excess odds ratio per gray for thyroid carcinoma was elevated (excess odds ratio per gray 11.66), it was not statistically significant (P = 0.12). No radiation risks were identified for other thyroid diseases. CONCLUSION: Our results suggest that in utero exposure to radioiodines may have increased the risk of thyroid carcinoma approximately 20 yr after the Chernobyl accident, supporting a conservative approach to medical uses of I-131 during pregnancy.
Authors: J M Bidart; L Lacroix; D Evain-Brion; B Caillou; V Lazar; R Frydman; D Bellet; S Filetti; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2000-11 Impact factor: 5.958
Authors: Kenneth J Kopecky; Valery Stepanenko; Nikolai Rivkind; Paul Voillequé; Lynn Onstad; Vladimir Shakhtarin; Evgeni Parshkov; Sergei Kulikov; Evgeni Lushnikov; Alexander Abrosimov; Vladislav Troshin; Galina Romanova; Vladimir Doroschenko; Anatoli Proshin; Anatoly Tsyb; Scott Davis Journal: Radiat Res Date: 2006-08 Impact factor: 2.841
Authors: Mykola D Tronko; Geoffrey R Howe; Tetyana I Bogdanova; Andre C Bouville; Ovsiy V Epstein; Aaron B Brill; Illya A Likhtarev; Daniel J Fink; Valentyn V Markov; Ellen Greenebaum; Valery A Olijnyk; Ihor J Masnyk; Victor M Shpak; Robert J McConnell; Valery P Tereshchenko; Jacob Robbins; Oleksandr V Zvinchuk; Lydia B Zablotska; Maureen Hatch; Nickolas K Luckyanov; Elaine Ron; Terry L Thomas; Paul G Voillequé; Gilbert W Beebe Journal: J Natl Cancer Inst Date: 2006-07-05 Impact factor: 13.506
Authors: André Bouville; Illya A Likhtarev; Lina N Kovgan; Victor F Minenko; Sergei M Shinkarev; Vladimir V Drozdovitch Journal: Health Phys Date: 2007-11 Impact factor: 1.316
Authors: I Likhtarov; L Kovgan; M Chepurny; O Ivanova; Z Boyko; G Ratia; S Masiuk; V Gerasymenko; V Drozdovitch; V Berkovski; M Hatch; A Brenner; N Luckyanov; P Voillequé; A Bouville Journal: Health Phys Date: 2011-06 Impact factor: 1.316
Authors: Jonathan M Samet; Amy Berrington de González; Lawrence T Dauer; Maureen Hatch; Ourania Kosti; Fred A Mettler; Merriline M Satyamitra Journal: Radiat Res Date: 2017-11-14 Impact factor: 2.841
Authors: Gila Neta; Maureen Hatch; Cari M Kitahara; Evgenia Ostroumova; Elena V Bolshova; Valery P Tereschenko; Mykola D Tronko; Alina V Brenner Journal: Radiat Res Date: 2014-03-10 Impact factor: 2.841
Authors: Elizabeth K Cahoon; Eldar A Nadyrov; Olga N Polyanskaya; Vasilina V Yauseyenka; Ilya V Veyalkin; Tamara I Yeudachkova; Tamara I Maskvicheva; Victor F Minenko; Wayne Liu; Vladimir Drozdovitch; Kiyohiko Mabuchi; Mark P Little; Lydia B Zablotska; Robert J McConnell; Maureen Hatch; Kamau O Peters; Alexander V Rozhko; Alina V Brenner Journal: J Clin Endocrinol Metab Date: 2017-07-01 Impact factor: 5.958